A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; plus /- endocrine therapy), or non-small-cell lung cancer (NSCLC)

被引：0

作者：

Yee, D. ^{[1
]}

Prat, A. ^{[2
]}

Sablin, M. P. ^{[3
]}

Iwata, H. ^{[4
]}

Johnston, E. L. ^{[5
]}

Bogenrieder, T. ^{[6
]}

Serra, J. ^{[7
]}

Hua, H. ^{[8
]}

LoRusso, P. ^{[9
]}

机构：

[1] Univ Minnesota, Masonic Med Ctr, Minneapolis, MN 55455 USA

[2] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[3] Inst Curie, Oncol Med, Paris, France

[4] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[5] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA

[6] Boehringer Ingelheim RCV, Clin Oncol, Vienna, Austria

[7] Boehringer Ingelheim Espana, Clin Oncol, Barcelona, Spain

[8] Boehringer Ingelheim China Investment Co, Clin Oncol, Shanghai, Peoples R China

[9] Yale Univ, Yale Canc Ctr, New Haven, CT USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

90TiP

引用

页数：1